NCT06199908 2024-07-26
AMT-562 in Patients With Selected Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1 Unknown
Clinical Trials
54 trialsNCT05164458 2023-12-28
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT06092268 2023-10-23
A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Unknown
NCT06082570 2023-10-13
A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Unknown
NCT05267899 2023-09-26
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
Zhejiang Haichang Biotech Co., Ltd.
Phase 1 Unknown
NCT06047431 2023-09-21
A Study of QL1706H in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05509985 2023-08-14
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
AskGene Pharma, Inc.
Phase 1 Unknown
NCT05976906 2023-08-04
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Zhejiang University
Phase 1 Unknown
NCT05972460 2023-08-02
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT04856150 2023-07-27
A Study of Q-1802 in Patients With Advanced Solid Tumors
QureBio Ltd.
Phase 1 Unknown
NCT05942378 2023-07-12
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
Fudan University
Phase 1 Unknown
NCT05862831 2023-05-17
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
Biotheus Inc.
Phase 1/2 Unknown
NCT05818917 2023-04-19
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05171790 2023-04-07
A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05768321 2023-03-16
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
GenEros Biopharma Ltd
Phase 1 Unknown
NCT05554666 2023-03-01
A Study of ASKG315 in Patients With Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1 Unknown
NCT05234853 2023-01-20
Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors
Purinomia Biotech, Inc.
Phase 1 Unknown
NCT05537987 2023-01-20
Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
InnoCare Pharma Inc.
Phase 1 Unknown
NCT05688605 2023-01-18
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
Shanghai Miracogen Inc.
Phase 1/2 Unknown
NCT05214976 2022-12-22
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT05649761 2022-12-14
A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04450901 2022-12-05
Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors
Y Biologics Inc.
Phase 1/2 Unknown
NCT05609019 2022-11-08
A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05114759 2022-10-12
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT05457517 2022-09-27
A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Unknown
NCT05502393 2022-08-16
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT05349409 2022-06-30
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT05278832 2022-03-14
A Study of QLS31905 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05254665 2022-02-24
A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05194709 2022-02-02
Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors
Wuxi People's Hospital
Phase EARLY_PHASE1 Unknown
NCT04471675 2022-01-31
Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT04811118 2022-01-31
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05114915 2022-01-31
A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05125523 2022-01-25
A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05153096 2022-01-03
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
NovaRock Biotherapeutics, Ltd
Phase 1 Unknown
NCT05172856 2021-12-29
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT05072522 2021-10-11
A Study of SKLB1028 in Patients With Advanced Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT04699643 2021-01-07
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Phase 1/2 Unknown
NCT04623892 2020-11-10
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04262739 2020-10-20
MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors
Haim Bio Co., Ltd.
Phase 1 Unknown
NCT04408079 2020-07-08
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04309968 2020-06-09
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT03415659 2020-02-17
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Phase 1 Unknown
NCT03897283 2019-10-30
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03641794 2019-08-01
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT03472352 2018-03-21
Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Unknown
NCT03439761 2018-03-16
An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT02940132 2017-12-06
A Study of SC10914 in Patients With Advanced Solid Tumors
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT01847118 2015-03-24
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT01337310 2012-03-13
Study of Tesetaxel in Japanese Patients With Solid Tumors
Genta Incorporated
Phase 1 Unknown